A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine (OGSG 1302)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 07 Oct 2018 Planned End Date changed from 31 Dec 2019 to 19 Dec 2018.
- 20 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.